Replies to post #115947 on Biotech Values

[HattieTheWitch]

You’re overlooking one very important point: An at-risk cannot happen if the Judge imposes a preliminary injunction. Therefore, we may infer that Teva would surely want a speedy discovery process if it had any intention whatsoever of launching generic Lovenox in the next couple of years.

Yes, but IF t-enox is approved, and TEVA wants to launch at risk, and MNTA gets its injunction, wouldn't TEVA be in the right to say "Hey, we just got approval and an injunction tossed our way, so it's not appropriate to have our hands tied for 1+ years when the matter could be more quickly handled"? "In the meanwhile, we're losing out on some real money, your honor, so how about it?"